Vascular response to angiotensin II predicts long-term prognosis in patients undergoing coronary artery bypass grafting

被引:15
作者
van der Harst, P
Volbeda, M
Voors, AA
Buikema, H
Wassmann, S
Böhm, M
Nickenig, G
van Gilst, WH
机构
[1] Univ Groningen, Fac Med Sci, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Cardiol, Groningen, Netherlands
[3] Univ Saarland, Innere Med Klin 3, D-66424 Homburg, Germany
关键词
angiotensin II; resistance; vasoconstriction; risk factors; coronary artery disease;
D O I
10.1161/01.HYP.0000147823.50497.a9
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Persistent activation of the renin-angiotensin system leads to downregulation of the angiotensin type-1 receptor, and consequently, to a decreased response to exogenous angiotensin II. In the present study, we investigated the association of angiotensin II responsiveness to clinical outcome after coronary artery bypass grafting (CABG). We studied the responsiveness to exogenous angiotensin II in human thoracic artery preparations of 114 CABG patients. Mean duration of follow-up was 7.3 +/- 0.1 years, during which 21 patients experienced a cardiovascular event. A diminished response to angiotensin II remained in multivariate Cox regression analysis, after adjustment for sex, age, blood pressure, and number of diseased coronary arteries, the strongest predictor for cardiovascular events ( relative risk, 3.37 [95% confidence interval, 1.20 to 9.51]; P = 0.022). Furthermore, diminished response to angiotensin II was associated with an increased mean arterial pressure (102.85 +/- 1.38 versus 97.40 +/- 1.37; P = 0.003) and a nonsignificant increase in angiotensin-converting enzyme activity, suggestive for a persistently activated renin-angiotensin system. In conclusion, these results suggest that in patients undergoing CABG, a diminished vascular responsiveness of the thoracic artery to exogenous angiotensin II is related to an increased risk of future cardiovascular events.
引用
收藏
页码:930 / 934
页数:5
相关论文
共 23 条
  • [1] Asano K, 1997, CIRCULATION, V95, P1193
  • [2] Buikema H, 1996, EUR HEART J, V17, P787
  • [3] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [4] European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice
    De Backer, G
    Ambrosioni, E
    Borch-Johnsen, K
    Brotons, C
    Cifkova, R
    Dallongeville, J
    Ebrahim, S
    Faergeman, O
    Graham, I
    Mancia, G
    Cats, VM
    Orth-Gomér, K
    Perk, J
    Pyörälä, K
    Rodicio, JL
    Sans, S
    Sansoy, V
    Sechtem, U
    Silber, S
    Thomsen, T
    Wood, D
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (17) : 1601 - 1610
  • [5] REGULATION BY ANGIOTENSIN-II OF ITS RECEPTORS IN RESISTANCE BLOOD-VESSELS
    GUNTHER, S
    GIMBRONE, MA
    ALEXANDER, RW
    [J]. NATURE, 1980, 287 (5779) : 230 - 232
  • [6] Kokkonen JO, 1997, CIRCULATION, V95, P1455
  • [7] LASSEGUE B, 1995, MOL PHARMACOL, V48, P601
  • [8] 2 DISTINCT PATHWAYS IN THE DOWN-REGULATION OF TYPE-1 ANGIOTENSIN-II RECEPTOR GENE IN RAT GLOMERULAR MESANGIAL CELLS
    MAKITA, N
    IWAI, N
    INAGAMI, T
    BADR, KF
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 185 (01) : 142 - 146
  • [9] Neal B, 2000, LANCET, V356, P1955
  • [10] Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS study)
    Oosterga, M
    Voors, AA
    Pinto, YM
    Buikema, H
    Grandjean, JG
    Kingma, JH
    Crijns, JHGM
    van Gilst, WH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (05) : 542 - 546